News stories about Sanofi (NYSE:SNY) have trended somewhat positive this week, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sanofi earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.3596680533064 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- Assuming Stock Value with Annual Performance Statistic for: Sanofi (NYSE:SNY) (finherald.com)
- Sanofi (SAN) Market Emerging Trends and New Developments Analysis 2018 (businessservices24.com)
- Key Findings of the Viscosupplementation Market including key players Sanofi, Anika Therapeutics (journalhealthcare.com)
- In-Depth Research: Rifampicin Market by Leading key players | Sanofi, Wellona Pharma, ASIAN PHARMACY (journalhealthcare.com)
- Type 2 Diabetes Market increasing demand with key players: Novo Nordisk, Sanofi, Merck (journalhealthcare.com)
Several brokerages recently commented on SNY. Liberum Capital raised shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Friday, March 23rd. Deutsche Bank reaffirmed a “buy” rating on shares of Sanofi in a research report on Monday, March 12th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $45.00 price objective (down from $50.00) on shares of Sanofi in a research report on Thursday, February 8th. ValuEngine lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Cowen set a $48.00 price objective on shares of Sanofi and gave the company a “hold” rating in a research report on Monday, December 18th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $49.33.
Sanofi (NYSE:SNY) last issued its quarterly earnings results on Wednesday, February 7th. The company reported $0.62 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.69 by ($0.07). Sanofi had a return on equity of 24.30% and a net margin of 23.25%. The business had revenue of $8.69 billion during the quarter, compared to analyst estimates of $8.65 billion. During the same quarter last year, the company posted $1.25 EPS. Sanofi’s quarterly revenue was down 2.1% compared to the same quarter last year. equities research analysts predict that Sanofi will post 3.36 earnings per share for the current fiscal year.
The firm also recently declared an annual dividend, which will be paid on Monday, June 4th. Investors of record on Thursday, May 10th will be issued a $1.8609 dividend. This represents a yield of 4.72%. The ex-dividend date of this dividend is Wednesday, May 9th. This is an increase from Sanofi’s previous annual dividend of $1.58. Sanofi’s dividend payout ratio is 35.14%.
WARNING: “Sanofi (SNY) Receives Media Impact Rating of 0.15” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3344242/sanofi-sny-receives-media-impact-rating-of-0-15.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.